Respiratory Syncytial Virus Vaccines

Abstract

7. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definition, mechanisms, relative outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818-24 8. Gattinoni L, Bombino M, Pelosi P, et al. Lung structure and function in different stages of severe acute respiratory distress syndrome. JAMA 1994; 271: 1772-9 9. Newth CJL, Stretton M, Deakers TW, Hammer J. Assessment of pulmonary function in the early phase of ARDS in pediatric patients. Pediatr Pulmonol 1997; 23: 169-75 10. Timmons OD, Havens PL, Fackler JC. Predicting death in pediatric patients with acute respiratory failure. Pediatric Critical Care Study Group. Extracorporeal Life Support Organization. Chest 1995; 108: 789-97 11. Sanchez I, De Koster J, Powell RE, Wolstein R, Chernick V. Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis. J Pediatr 1993; 122: 145-51 12. Patel NR, Hammer J, Nichani S, Numa A, Newth CJ. Effect of inhaled nitric oxide on respiratory mechanics in ventilated infants with RSV bronchiolitis. Intensive Care Med 1999; 25: 81-7 13. Abman SH, Griebel JL, Parker DK, Schmidt JM, Swanton D, Kinsella JP. Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure.

Community and nosocomially acquired respiratory syncytial virus infection in a German paediatric hospital from 1988 to 1999

“…Therefore, prevention of RSV infection should be a major goal of national health strategies also from an economic point of view, and probably should not be restricted only to the high risk population. This statement does not apply to any kind of passive immunisation, but to a potential active vaccine [4].…”

“…They are, however, urgently needed for estimates of the disease burden in view of existing or forthcoming immunoprophylaxis or vaccines [4,14]. Today, an enriched intravenous immunoglobulin preparation and a protective humanised monoclonal antibody directed against the highly conserved F-protein of RSV are available, but both require repeated application and are highly expensive [1,14,17,24,25].…”

Therapy for respiratory tract infections caused by respiratory syncytial virus

“…The mechanism responsible for this vaccineassociated enhanced disease is still not completely understood. There are indications that formalin changes viral epitopes responsible for the generation of neutralising antibodies [13]. In addition, from animal studies it became clear that a natural infection with RSV elaborates a Th-1-like response whereas the FI-RSV vaccine leads to a Th-2-like response giving rise to increased airway in¯ammation [13].…”

Immunisation in the current management of cystic fibrosis patients

“…Respiratory syncytial virus (RSV) is the most important cause of viral lower respiratory tract infection (LRTI) in infants and children worldwide [93,94]. RSV consists of two major antigenic groups, A and B strains, the A strains being found predominantly in the community [93,95].…”